• Breathtaking science

    Developing innovative therapeutics to transform

    the standard of care for respiratory diseases

  • Search for better science

    We aim to build a strong clinical R&D pipeline to

    target debilitating respiratory diseases

  • Our science

    Targeting respiratory diseases with significant unmet medical needs.

    There are millions of patients suffering globally from chronic, debilitating respiratory conditions that are not well treated by existing medicines. There is a real and pressing need for new treatments. We are focused on developing these treatments. Our efficient R&D outsourcing model gives us access to leading experts and organisations around the globe and our agility and focus on our core competencies provide the highest standards of pre-clinical and clinical development. 

    See our product pipeline

    Our strategy

    To progress projects with high commercial potential, whilst delivering both near-and long-term value to our shareholders.

    We have a clear view of the medical need and commercial potential of our novel products in global, multi-billion dollar markets. Making the right decisions now, with partners and investors, will help us identify the quickest and most effective route to market allowing us to potentially transform the lives of patients suffering from these debilating diseases, with the returns enabling us to continue this mission into the future. 

    Find out more about us

Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.

Webcast: Investor & Analyst R&D Forum London 2019

Clinical COPD data published

Clinical asthma data published

Latest press releases

15 October 2019

Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Phar…

19 September 2019

Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive interim data from a Phase 2 trial with its dry powder inhaler formulation of ensifentrine in chronic obstructive pulmonary disease (“COPD”) at the European Respiratory Society (“ERS”) International Congress on Sunday, September 29, 2019 at…


Watch our latest video

COPD: I can't breathe


Current share price


0.00 (0.00%)



-0.12 (-2.95%)


Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

E: info@veronapharma.com
T: +44 (0)203 283 4200



Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
Argot Partners
E: verona@argotpartners.com
T: +1 212 600 1902

European Investor relations contact
Optimum Strategic Communications
E: verona@optimumcomms.com
T: +44 (0)203 950 9144

Nominated adviser and broker
Nplus1 Singer Advisory LLP
One Bartholomew Lane
London EC2N 2AX
United Kingdom

T: +44 (0)203 283 4200


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us